Submitted by reuters8361 in business
Eli Lilly <a href="https://www.reuters.com/markets/companies/LLY.N" target="_blank">(LLY.N)</a> on Tuesday said its recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost $550 a month for customers whose health insuran…